- Home
- XCUR vs LUCD Comparison
XCUR vs LUCD Comparison
Compare XCUR & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XCUR
- LUCD
- Stock Information
- Founded
- XCUR 2011
- LUCD 2018
- Country
- XCUR United States
- LUCD United States
- Employees
- XCUR N/A
- LUCD N/A
- Industry
- XCUR Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- XCUR Health Care
- LUCD Health Care
- Exchange
- XCUR Nasdaq
- LUCD Nasdaq
- Market Cap
- XCUR 43.6M
- LUCD 51.6M
- IPO Year
- XCUR N/A
- LUCD 2021
- Fundamental
- Price
- XCUR $13.22
- LUCD $1.28
- Analyst Decision
- XCUR
- LUCD Strong Buy
- Analyst Count
- XCUR 0
- LUCD 4
- Target Price
- XCUR N/A
- LUCD $3.63
- AVG Volume (30 Days)
- XCUR 47.7K
- LUCD 776.7K
- Earning Date
- XCUR 11-14-2024
- LUCD 03-24-2025
- Dividend Yield
- XCUR N/A
- LUCD N/A
- EPS Growth
- XCUR N/A
- LUCD N/A
- EPS
- XCUR N/A
- LUCD N/A
- Revenue
- XCUR $500,000.00
- LUCD $4,189,000.00
- Revenue This Year
- XCUR N/A
- LUCD $91.72
- Revenue Next Year
- XCUR N/A
- LUCD $139.38
- P/E Ratio
- XCUR N/A
- LUCD N/A
- Revenue Growth
- XCUR N/A
- LUCD 179.27
- 52 Week Low
- XCUR $1.44
- LUCD $0.63
- 52 Week High
- XCUR $36.00
- LUCD $1.63
- Technical
- Relative Strength Index (RSI)
- XCUR 59.25
- LUCD 50.21
- Support Level
- XCUR $10.10
- LUCD $1.18
- Resistance Level
- XCUR $14.44
- LUCD $1.47
- Average True Range (ATR)
- XCUR 1.86
- LUCD 0.15
- MACD
- XCUR 0.38
- LUCD -0.04
- Stochastic Oscillator
- XCUR 72.77
- LUCD 32.50
About XCUR Exicure Inc.
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.